Scavenging Reactive Oxygen Species Production Normalizes Ferroportin Expression and Ameliorates Cellular and Systemic Iron Disbalances in Hemolytic Mouse Model

Naveen Kumar Tangudu,1 Betül Alan,1 Francesca Vinchi,2 Katharina Wörle,3 Dilay Lai,1 Sabine Vettorazzi,1 Kerstin Leopold,3 and Maja Vulić Spasić1

Abstract

Aims: Release of large amounts of free heme into circulation, overproduction of reactive oxygen species (ROS), and activation of toll-like receptor-4-dependent responses are considered critical for the ability of heme to promote oxidative stress and to initiate proinflammatory responses, posing a serious threat to the body. A deep understanding of the consequences of heme overload on the regulation of cellular and systemic iron homeostasis is, however, still lacking.

Results: The effects of heme on iron metabolism were studied in primary macrophages and in mouse models of acute and chronic hemolysis. We demonstrated that hemolysis was associated with a significant depletion of intracellular iron levels and increased expression of the sole iron exporter protein, ferroportin. The pathophysiological relevance of this mechanism was further demonstrated in sickle cell anemia mice, which, despite chronic hemolysis, maintained high ferroportin expression and increased iron export. We identified a redox active iron species and superoxide as regulators for ferroportin induction by heme. Scavenging the ROS production, by use of a pharmacological antioxidant N-acetylcysteine, prevented ferroportin induction and normalized intracellular iron levels in macrophages and in experimentally induced hemolysis in mice.

Innovation: Our data propose that scavenging ROS levels may be a novel therapeutic strategy to balance intracellular iron levels and systemic iron influx in conditions associated with heme overload.

Conclusion: This study identifies that the pro-oxidant, and not the proinflammatory, actions of heme profoundly impact on iron homeostasis by critically regulating the expression of ferroportin and iron export in hemolytic conditions. Antioxid. Redox Signal. 29, 484–499.

Keywords: heme, oxidative stress, ROS, macrophages, ferroportin, antioxidants

Introduction

During oxidative stress conditions caused by pathological hemolytic diseases and certain bacterial infections, extensive cell damage (hemolysis) occurs. This results in the release of large amounts of hemoglobin and free heme into circulation. Up to 20–280 μM heme can be found in patients suffering from sickle cell disease or thalassemia compared with 0.2 μM heme in healthy volunteers (40, 43). Once released into the blood, free heme and hemoglobin are rapidly scavenged by the plasma proteins hemopexin and haptoglobin, respectively, and cleared from the blood by macrophages and hepatocytes via receptor-mediated endocytosis [reviewed in Ref. (7)]. Within the cell, heme is...
Heme, in a concentration range found during hemolytic episodes, increases intracellular reactive oxygen species (ROS) production, which, in turn, signal for the induction of the unique iron exporter ferroportin, subsequently causing iron export from macrophages. These events profoundly affect tightly controlled cellular and systemic iron levels. Given our findings that scavenging ROS production prevented ferroportin induction by heme and normalized iron levels in mice undergoing experimentally induced hemolysis, we envision that pharmacologic antioxidants may be an attractive therapeutic tool to leverage physiological iron levels in conditions wherein heme and ROS levels are high, such as in chronic hemolytic conditions.

In particular, the release of iron after heme catabolism and the activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase complex have been considered critical for the ability of heme to generate ROS and to promote oxidative stress (2, 5, 7, 28, 42, 49). In addition, as an extracellular signaling damage-associated molecule, heme binds to the pattern recognition toll-like receptor-4 (TLR4) (18) and promotes sterile inflammation and the activation of the innate immune responses (15, 16, 33, 55), resulting in increased cytokine and lipid mediator production from macrophages (19), enhanced expression of adhesion molecules, and tissue factors on endothelial cells (4, 5, 56). By doing so, heme exacerbates the pathogenesis of hemolytic disorders. Although heme-induced cytokine expression depends on functional TLR4, ROS production in response to heme is not dependent on TLR4 signaling (18).

The effects of heme are further potentiﬁed by virtue of its capacity to induce ferroportin, the unique iron-export protein encoded by Slec40a1 gene (14, 57, 58). High ferroportin levels were measured in macrophages upon heme overload and erythropagocytosis (12, 13, 31, 32, 37) and in hemolytic murine models of β-thalassemia and phenylhydrazine-induced hemolytic anemia (11, 22, 34).

At the molecular level, induction of ferroportin by heme was shown to be depending on concerted actions between transcriptional regulators Bach1 (Btb and Cnc homology 1) and Nrf2 (nuclear factor erythroid-derived 2-related factor 2), and the binding of the small Maf proteins to Maf recognition elements/antioxidant response elements, located in the promoter region of ferroportin gene (37). Although the transcriptional activation of ferroportin correlated with increase in its protein levels, the most effects of heme on ferroportin protein synthesis were attributed to iron released upon heme catabolism; namely, by using an iron chelator, the increase in ferroportin protein levels by heme was prevented (13, 32). In addition, ferroportin undergoes post-translational control by the systemic iron regulator, hepcidin, whereby binding of hepcidin to ferroportin causes its internalization and degradation, leading to iron retention within the cells (21, 41).

Despite the accumulated evidence showing that heme-induced ferroportin expression in heme- and iron-dependent manner in primary macrophages and macrophage cell lines, and the fundamental role of ferroportin in the regulation of iron metabolism, a deep understanding of the consequences of heme overload on cellular and systemic iron responses in vivo is, however, still lacking.

In this work, we demonstrate that heme, by its pro-oxidative capability, induces ferroportin and perturbs tightly balanced cellular and systemic iron levels in mouse models of hemolytic conditions. We show that overproduction of ROS by heme underlies ferroportin induction, since scavenging ROS by the use of pharmacological antioxidant N-acetylcysteine prevents ferroportin induction and normalizes iron levels in macrophages and experimentally induced hemolysis in mice. This study reveals the integration between heme and iron metabolism at the level of ferroportin and raises the possibility that limiting the pro-oxidant activities of heme may leverage homeostatic iron responses in hemolytic conditions.

Results

Acute and chronic hemolysis in mice promote iron export from the macrophages via ferroportin induction

The first objective of this study was to investigate the consequences of heme overload on cellular and systemic iron metabolism in experimental mouse models of acute and chronic heme overload.

Acute hemolysis was induced by infusing mice intravenously with heme (35 μmol heme/kg). Hematological analysis revealed that severe lysis of erythrocytes and decrease in hemoglobin occurred shortly upon heme infusion (Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/ars), corroborating the concept that excess of free heme enhanced the hemolytic process by impairing erythrocyte integrity (9, 23, 26). We further showed that heme was quickly catabolized in macrophages in a process that associated with significant induction of Hmox-1 mRNA and with the lack of heme accumulation in the spleen of infused mice (Fig. 1A, B) (53). This suggested that iron, as a product of heme catabolism, may either be stored or exported from the cells.

To address this issue, we measured iron levels in the spleen of infused mice and evaluated the expression of the sole iron exporter protein, ferroportin. Our data revealed that in the conditions of acute heme overload, iron was rapidly exported from the cells, as a significant drop in iron levels in the spleen was detected by the analysis of the nonheme iron content in the spleen of infused mice, and by Perl’s staining for iron deposits on spleen sections (Fig. 1C, D). Moreover, we demonstrated that acute heme overload in mice caused for a significant induction in ferroportin mRNA and protein expression, which was maintained at a consistently high level throughout the course of heme infusion (Fig. 1E, F; see also original immunoblot files in Supplementary Data). This effect correlated with a transient elevation of circulating iron levels (Fig. 1G).

In contrast to the spleen, the livers of infused mice accumulated heme and significantly increased Hmox1 expression.
Fig. 2A, B), implying that heme was taken up by the hepatocytes and transiently stored (52, 53). The liver responded to heme overload by upregulating the transcription of hepcidin, the iron responsive hormone in a time-dependent manner (Fig. 2C). No obvious iron overload was observed in the livers of heme-infused mice (Fig. 2D), despite elevated plasma iron levels (Fig. 1G) and increased transferrin saturation (59.4 ± 6.8 in infused mice versus 34.9 ± 5.8 in control mice, p < 0.005). We further measured a more than twofold increase in ferroportin protein expression, however, the data were only marginally under the level of statistical significance (p < 0.07) (Fig. 2E). Heme infusion in mice did not affect nonheme iron levels in the duodenum (Fig. 2F).

The consequences of acute heme overload in mice on cellular and systemic iron metabolism, and particularly on modulating ferroportin expression, led us to explore the iron handling capacity of macrophages and ferroportin expression levels under conditions of chronic heme overload. To this end, we used a well-described mouse model of sickle cell disease, HbS mice (44).
Sustained hemolysis and continuous heme delivery into the tissues of HbS mice associated with increased ferroportin mRNA and protein expression, in the spleen and the liver of HbS mice (Fig. 3A, B, E, F). Similarly to acute heme overload, the spleen of HbS mice showed reduced iron content, demonstrated by Perls’ staining for iron depositions and by the analysis of nonheme iron levels in the spleen (Fig. 3C, D). These data suggested that during severe hemolysis, heme-mediated ferroportin induction and low hepcidin in HbS mice (11) served to elevate systemic iron availability, required to sustain high erythropoietic demands in these mice.

Our in vivo observations could be recapitulated in isolated macrophages, which upon stimulation with heme (25 μM; 16 h) demonstrated increased ferroportin mRNA and protein expression (Fig. 4A, B) and a significant decrease in the intracellular iron pool (2.2-fold; p < 0.01) (Fig. 4C). In a time-line experiment, we showed that heme loading of macrophages decreased the expression of heme–hemopexin complex receptor and transferrin receptor 1 (TfR1) (Fig. 4D), while ferritin levels remained largely unchanged except for an increase in ferritin levels at 16 h post-treatment (Fig. 4D).

**Heme and lipopolysaccharide polarize macrophages toward proinflammatory cells with two opposing iron phenotypes**

So far, our results established that in the conditions of acute and chronic heme overload, macrophages acquired high ferroportin expression and an efficient iron export. Consistently, exposure to heme promoted proinflammatory responses in macrophages (Fig. 4A). The observed effects are specific to heme, and possible contamination of heme preparation with lipopolysaccharide (LPS) has been excluded by measuring inflammatory markers after treating macrophages with polymyxin B and heme (Supplementary Fig. S1).

Importantly, the iron phenotype developed in response to heme overload contrasts the iron responses triggered by LPS, another potent proinflammatory Tlr4 ligand. We showed that stimulation of macrophages with LPS resulted in significant reduction in ferroportin mRNA and protein expression and enhanced intracellular iron deposition throughout all time points tested (Fig. 5A–D). Moreover, typical iron retention within the splenic macrophages and significant suppression of ferroportin were measured in mice after LPS injection (Fig. 5E–H). These results indicated that both heme and LPS polarized macrophages toward cells with proinflammatory characteristics, which associated with the development of two distinct iron phenotypes.

We further demonstrated that the proinflammatory Tlr4-dependent activities of both, heme and LPS, were dispensable for ferroportin regulation, since its expression levels were similar between Tlr4-deficient and control macrophages (Fig. 6). These results excluded the proinflammatory Tlr4 signaling capacity of heme and LPS, as mediator of ferroportin induction. The expression of proinflammatory...
cytokines was abolished by the lack of Tlr4 in response to heme and LPS treatment (Fig. 6), supporting previous findings (18, 19).

Overproduction of ROS after heme overload is critical for ferroportin induction in macrophages

Given that ferroportin induction by heme occurred in a manner independent of Tlr4 (Fig. 6A) and that ROS production in macrophages after heme overload did not require Tlr4 signaling (18, 19), we postulated that increased levels of intracellular ROS might be critical for ferroportin induction. The generation of free radicals by the Fenton reaction and the activation of NADPH oxidase complex have been considered the major form of ROS generated by heme (2, 28, 38). Therefore, the second objective of our study was to explore the potential contribution of ROS and, more precisely, of redox iron and superoxide to ferroportin induction by heme.

FIG. 3. Chronic hemolysis in mice is coupled with ferroportin induction and iron sparing of macrophages. (A, E) Relative mRNA expression of ferroportin (Fpn1) in the spleen and the liver, respectively, of HbS mice with regard to HbA controls measured by quantitative real-time PCR. (B, F) Western blot analysis and relative quantification of ferroportin protein levels indicated by bars, in the spleen and the liver, respectively, of HbS and HbA mice (C) The nonheme iron levels in the spleen and (D) Perls’ stainings of spleen sections (scale bar is 50 μm) of HbS and control HbA mice. Data are presented as mean ± SEM; n = 4–5 mice/group; *p-values <0.05, **p-values <0.005, ***p-values <0.0005. HbS mice, sickle cell disease mouse model. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.
The effect of iron, present within the heme moiety, was evaluated by treating macrophages with an iron-free heme analogue (protoporphyrin IX [PPIX]) and upon treatment of cells with heme in the presence of an iron chelator, desferoxamine (DFO).

We confirmed that the redox active iron, which is derived from heme catabolism in macrophages, is capable of catalyzing ROS formation (Fig. 7A) (19). By contrast, treatment of macrophages with PPIX failed to increase the ROS production and ferroportin expression, implying that iron within the heme moiety was required for the observed effects (Fig. 7B). In contrast, PPIX treatment of macrophages was capable of inducing Hmox-1 expression (Fig. 7C), indicating that PPIX was taken up by macrophages and catabolized (13). However, the lack of iron after PPIX catabolism reflects the observed lack of ROS production and ferroportin induction. Expectedly, and in line with previous report (13), treatment of macrophages with DFO abolished ferroportin and ferritin induction by heme, whereas TfR1 expression was lowered upon heme and combined treatment with heme and DFO (Fig. 7D).

Collectively, these results underscored the importance of catalytically active iron for enhanced ROS production and subsequent ferroportin induction.

We next explored the potential role of superoxide, which can be produced by several sources such as NADPH oxidase and xanthine oxidase, for ferroportin induction by heme. In our model, the contribution of NADPH oxidase and xanthine oxidase was evaluated by treating the macrophages with inhibitors such as apocynin and allopurinol, respectively. We
FIG. 5. LPS-triggered proinflammatory macrophages are characterized by low ferroportin expression and enhances iron deposition. (A) Bone marrow-derived macrophages from wild-type mice were treated with LPS (100 ng/mL; 4 h) or with vehicle (PBS). The mRNA expression of ferroportin (Fpn1) and inflammatory markers was measured by quantitative real-time PCR. (B) Time-line of ferroportin mRNA expression upon treatment of BMDMs with LPS (100 ng/mL) was measured by quantitative real-time PCR. (C) Western blot analysis of ferroportin (Fpn1) protein levels and relative quantification, indicated in histograms, upon treatment of BMDMs with LPS (100 ng/mL) for 16 and 24 h. (D) The intracellular iron content upon LPS stimulation of macrophages at indicated time points was measured using total-reflection X-ray fluorescence spectrometer method; n = 3–4/group. Wild-type mice were injected with a single sublethal dose of LPS (5 μg LPS; for 6 h). (E) The iron deposition was analyzed by Perls' staining of the spleen sections; scale bar is 50 μm. (F) Nonheme iron content in the spleen of LPS-injected versus vehicle-injected mice. (G, H) mRNA expression and protein levels of ferroportin were analyzed by quantitative real-time PCR and Western blot analysis, respectively. n = 4–6 mice/group. Data are presented as mean ± SEM. *p-values < 0.05, **p-values < 0.005, ***p-values < 0.0005. i.p., intraperitoneal; LPS, lipopolysaccharide. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.
showed that cotreatment of macrophages with heme and apocynin (Fig. 7E), as well as with heme and allopurinol (Fig. 7F), fully prevented ferroportin induction by heme. These data revealed that inhibiting superoxide at its production site is an effective way to counteract heme-mediated ferroportin induction.

By contrast, in the presence of another ROS species, such as nonradical hydrogen peroxide, ferroportin expression in macrophages was not increased but significantly downregulated (Supplementary Fig. S2). Given the increased ROS levels (which include the production of hydroxyl radicals from hydrogen peroxide and ferrous iron in Fenton chemistry), one may argue that treatment of cells with hydrogen peroxide may cause ferroportin induction. In our experimental setting, we used high concentrations of hydrogen peroxide that may not fully mimic the levels of hydrogen peroxide produced by macrophages after heme overload. Future studies may address how different concentrations of hydrogen peroxide and/or sustained nontoxic hydrogen peroxide levels affect ferroportin expression and whether these effects are present in conditions characterized by heme overload.

Our findings identify redox active iron and superoxide, derived from NADPH oxidase and xanthine oxidase, as sources of ROS critical for ferroportin induction in heme-loaded macrophages.

Scavenging ROS production after heme overload restores ferroportin expression and normalizes iron levels in the spleen

We next evaluated the effect of antioxidants on ferroportin induction by heme. To this end, we treated macrophages with heme in the presence of N-acetyl-L-cysteine (NAC), a glutathione precursor that acts as a broad antioxidant (Fig. 8A). We showed that NAC treatment scavenged ROS production and, more importantly, it counteracted ferroportin induction by heme (Fig. 8B, C). In parallel to ferroportin, the expression of Hmox-1 was increased by heme-triggered ROS production and its induction was prevented by the combined treatment with NAC and heme (Fig. 8B). These data revealed that scavenging ROS where high ROS production already occurred in the system is another promising approach to reducing heme-dependent ferroportin expression.

To validate these in vitro observations at systemic levels, wild-type mice were injected with NAC (500 mg/kg, i.p.) 1 h before inducing heme overload (35 μmol heme/kg). We showed that increase in ferroportin mRNA and protein expression by heme was effectively prevented in mice receiving combined treatment of NAC and heme (Fig. 8D, E). Similarly, the induction of Hmox1 by heme was abolished by cotreatment with NAC and heme, supporting our in vitro
findings (Fig. 8D). Consequently, iron was retained within the macrophages of the spleen, as demonstrated by the measurement of nonheme iron levels and by Perls’ staining for iron deposition (Fig. 8F, G). These results revealed that scavenging ROS production was an efficient way to normalize ferroportin expression and iron levels in mice during acute hemolysis.

**Discussion**

Our study highlights the pro-oxidant actions of heme as a critical trigger of cellular and systemic iron disturbances in hemolytic conditions. We show that heme, in a concentration range found during hemolytic episodes, increases intracellular ROS production and consequential signals for ferroportin induction and subsequent iron export from the macrophages. We propose that this, previously unrecognized, in vivo mechanism may represent an important crossroad between heme and iron metabolism, which allows the cell to balance iron deposition and export on the basis of heme uptake.

The finding that heme induces ferroportin is not novel. Previous studies demonstrated that upon exposure of macrophages to heme, or after erythrophagocytosis, ferroportin transcription is upregulated, and its expression on the cell membrane is increased (13, 32). However, those studies were conducted in vitro using primary macrophages and macrophage cell lines. To the best of our knowledge, this is the first
FIG. 8. Scavenging heme-triggered ROS production prevents ferroportin induction and normalizes iron levels in the spleen during experimentally induced hemolysis in mice. BMDMs were treated with heme, NAC, or in combined treatment with heme and NAC. (A) The levels of ROS were measured using fluorescence derived from DCFH2-DA dye metabolism and quantified using fluorescence microplate reader. (B) Relative ferroportin (Fpn1) and Hmox1 mRNA expression levels were measured using quantitative real-time PCR and normalized to Gapdh. (C) Western blot analysis and relative quantification of ferroportin protein levels using ImageJ software in BMDMs treated with heme in the presence or absence of NAC. Acute hemolysis was induced in mice (i.v. 35 μmol heme/kg body weight) for 1 h. Mice received combined treatment of heme and NAC (500 mg/kg NAC 1 h before heme injections) or NAC alone (500 mg/kg; for 1 h). (D) Relative mRNA expression of ferroportin (Fpn1) and Hmox-1 in the spleen of control, heme-, NAC, and NAC+heme-injected mice analyzed by quantitative real-time PCR and normalized to Gapdh. (E) Western blot analysis of ferroportin in the spleen from mice after heme, NAC, or NAC+heme injections. Ferroportin levels were quantified using ImageJ software and band intensity is represented in histogram. (F) Perls’ staining for iron deposits in the spleen. Scale bar is 100 μm. (G) The levels of nonheme iron in the spleen of heme-injected, NAC, or NAC+heme-injected mice; n = 4–5 mice/group. Data are presented as mean±SEM. *p-values <0.05, **p-values <0.005, ***p-values <0.0005. NAC, N-acetyl-L-cysteine. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.
Our results point to an intrinsic macrophage iron circuitry that is established in hemolytic conditions and is maintained even when systemic effects of heme are evoked. For example, in the conditions of pathological heme overload, such as in sickle cell mice, sustained heme delivery into macrophages contributes to continuous transcriptional and translational activation of ferroportin and for an effective iron export from the cells. This mechanism is further boosted by erythropoietic stimuli, which, by suppressing hepcidin expression, potentiate ferroportin stabilization and iron export into the blood (11, 30).

Similar to chronic heme overload conditions, high ferroportin mRNA and protein expression and increased plasma iron and transferrin-bound iron levels were present during acute hemolysis. Under this condition, however, the liver fails to suppress hepcidin expression, reinforcing the view that heme, released as a consequence of intravascular hemolysis, may predominate over hepcidin for the regulation of ferroportin expression. We propose that proinflammatory capacities of heme, rather than increased levels of circulating iron/transferrin-bound iron, signal for hepcidin activation during acute hemolysis. This is supported by the finding that hepcidin induction by heme required Tlr4 signaling (32a) and by the lack of iron deposition in the liver during acute heme overload despite increased plasma/transferrin-bound iron levels (Fig. 2D).

Our data are consistent with the findings that macrophages adopt the characteristics of proinflammatory cells when exposed to an excess of heme (18, 51). Binding of heme to Tlr4 requires the presence of iron within the porphyrin ring of heme and is likely to occur via receptor binding site different from that established between Tlr4 and LPS (18). The novelty of our study is the finding that heme and LPS, despite both retaining the ability to bind to Tlr4 and to activate receptor-mediated immune responses, polarize macrophages toward proinflammatory cells with two opposing iron phenotypes. Under heme overload conditions, macrophages acquire an iron phenotype characterized by low intracellular iron and high ferroportin expression. This dramatically contrasts the iron phenotype that develops in response to LPS, hallmarked by high intracellular iron levels and low ferroportin expression (10, 20, 48).

The opposing actions of LPS and heme on ferroportin regulation and iron status might be explained by the differential requirements for iron by the host during inflammation/infections and in hemolytic conditions: by suppressing ferroportin expression during inflammation/infection, macrophages retain iron thereby limiting its availability for pathogen growth. In contrast, heme, as a product of hemolysis and a mediator of sterile and nonsterile inflammation, sensitizes macrophages to acquire a proinflammatory phenotype and to enhance ferroportin expression and iron export.

**FIG. 9. Orchestration of heme and iron metabolism in macrophages at the level of ferroportin.** The proposed model illustrates the effects of antioxidants and ROS inhibitors on restoring macrophages iron homeostasis during hemolytic conditions. Increased ROS production by heme leads to transcriptional activation of ferroportin (Fpn1), increased ferroportin protein levels, and subsequent iron export from the cells. Preventing the release of free iron upon heme catabolism and the production of superoxide from NADPH oxidase and xanthine oxidase sources, by the use of selective inhibitors (such as iron chelator DFO, apocynin, and allopurinol, respectively), abolishes ferroportin induction by heme. In addition, antioxidants, such as NAC, which scavenge ROS production, prevent heme-triggered Fpn1 mRNA and protein induction and iron egress from the macrophages. NADPH, nicotinamide adenine dinucleotide phosphate. To see this illustration in color, the reader is referred to the web version of this article at www.liebertpub.com/ars.
into the circulation where iron is required for the erythropoiesis, or eventually, to ameliorate intracellular iron overload and toxicity.

Further innovative findings of our study are that increased ROS production during heme overload contributes to ferroportin induction and subsequent iron export from macrophages (Fig. 9). For this to occur, iron must be coordinated within the porphyrin ring of heme, since treatment of macrophages with the iron-free heme analogue, protoporphyrin IX, failed to increase both the ROS production and ferroportin expression. Moreover, depleting iron levels by the use of iron chelator DFO prevented ferroportin induction in heme-treated macrophages, re-emphasizing the role of iron for ferroportin induction. This is in line with previous studies, which demonstrated the central role of iron for translational regulation of ferroportin, proposing that this effect is mediated by mechanism that involved iron-responsive protein/iron-responsive elements regulatory network (39). The concept of iron-dependent ferroportin translation in macrophages has, however, been challenged by the generation of mice with selective ablation of Irp2 in macrophages (Irp2<sub>−/−</sub>ySHC<sup>C<sub>Cre</sub></sup> mice), which showed no changes in iron levels and ferroportin expression in macrophages (17). These data reinforce our concept of heme-driven ROS production as a driving force for ferroportin activation, a mechanism that is elicited by macrophages as defense response against iron toxicity and iron-catalyzed oxidative stress (Fig. 9).

Importantly, we demonstrated that treatment with antioxidant NAC, which is an effective scavenger of free radicals, successfully prevented heme-mediated ferroportin induction in vitro and in an experimental mouse model of acute heme overload. We believe that these findings could have implications on possible therapeutic strategies in conditions where heme and ROS levels are high. For example, scavenging ROS production by pharmacologic antioxidants in chronic hemolytic conditions may reduce iron efflux into the circulation and lower the generation of unwanted nontransferrin-bound iron fraction; this, in turn, would facilitate the delivery of transferrin-bound iron required for the erythropoiesis.

Antioxidants have already proven efficient in reducing at least some complications associated with sickle cell disease [reviewed in Refs. (8, 29)]. Blocking the pro-oxidant effects of heme was also demonstrated to be beneficial in preventing cell death, tissue damage, and lethality in models of malaria and sepsis, all characterized by heme excess (45). We suspect that rebalancing cellular and systemic iron homeostasis in these conditions might have contributed to the positive effects of antioxidants therapy.

In addition to antioxidants, which neutralize already produced ROS, treatments with drugs that specifically target ROS production at source should be reconsidered. Several enzymes in macrophages are capable of producing ROS themselves. Among those is NADPH oxidase, activation of which results in a burst of superoxide production (1, 3). Previous reports showed that the lack of gp91 phox subunit of NADPH oxidase in mice provided greater protection against oxidative stress during iron overload (49). Another study has shown that free heme induced migration and proliferation of vascular smooth muscle cells, a process dependent on the production of ROS derived from NADPH oxidase activity (38). Our study provides evidence that the increase in cellular oxidant levels, as a result of NADPH oxidase activity, was responsible for ferroportin induction by heme.

We suspect that preventing NADPH oxidase activity rather than, or in addition to, reducing the levels of already produced ROS may constitute a more targeted strategy to leverage cellular and systemic iron levels and reduce pathological consequences of heme/ROS in hemolytic conditions. This idea certainly deserves further investigation. As far as the molecular aspects are concerned, more studies are needed to provide deeper understanding of the mechanism accountable for our observations (Fig. 9).

Collectively, this study advances our current understanding of heme and iron (patho)physiology, identifies ROS species as critical mediators of ferroportin induction during heme overload, and proposes antioxidants as a promising therapeutic approach to restore iron levels in hemolytic conditions.

Materials and Methods

Animal experiments

C57BL/6J wild-type and Tlr4-deficient mice, all females, age between 8 and 12 weeks, were maintained on a standard mouse diet containing 200 mg/kg iron (Ssniff, Soest, Germany) under a constant dark–light cycle, and were allowed access to food and water ad libitum.

Heme overload in mice was induced by single intravenous (i.v.) injection of freshly prepared hemin (ferric protoporphyrin IX that is reduced to ferrous-protoporphyrin IX, heme, within cells; Sigma Aldrich, St. Louis) at a dosage of 35 μmol/kg of body weight. Hemin was dissolved in 0.1 N of sodium hydroxide (NaOH) and diluted in phosphate-buffered saline (PBS) at a final concentration of 20 mmol/L. pH was adjusted to 7.4 with 0.1 N of hydrochloric acid (HCl). Freshly prepared hemin was injected into the tail vein of mice at a dose of 35 μmol/kg. Control mice were injected with PBS (53). To scavenge the production of ROS, mice were injected intraperitoneally (i.p.) with NAC (500 mg/kg; LKT laboratories, Inc.) 1 h before heme injections. The term “heme” is used generically to refer to both heme and hemin.

Inflammation was induced in mice by single i.p. LPS injection (5 μg LPS; L2630, *Escherichia coli*, serotype 0111:B4, Sigma Aldrich, St. Louis) for 6 h.

Mice were sacrificed by CO2 inhalation. Heparinated blood was collected by cardiac puncture and hematological parameters were measured using Scilvet Animal Blood Counter (ABX Diagnostics, Montpellier, France). All animal experiments were approved by and conducted in compliance with the guidelines of the University Ulm Animal Care Committee and the Federal Authorities for Animal Research (Regierungspräsidium Tübingen, Baden-Wuerttemberg, Germany).

Spleen samples from control HbA and sickle HbS mice (44) have been provided by Professor Tolosano, University of Turin, Italy.

Preparation of bone marrow-derived macrophages and treatments

Femoral marrows from wild-type mice were flushed and cells were plated at density 1 × 10<sup>6</sup> cells/mL in culture petri dishes (Becton Dickinson) using Dulbecco’s minimal Eagles medium (Invitrogen) supplemented with 10% fetal bovine serum, 10 mM sodium pyruvate, 10 mM l-glutamine, penicillin, and streptomycin (Sigma Aldrich, St. Louis). The cells were differentiated
with 20% mouse L929 fibroblast cell line culture supernatant as a source for macrophage-colony stimulating factor. After 4 days of culture, nonadherent cells were removed and adherent cells, bone marrow-derived macrophages (BMDMs), were washed twice with PBS and the medium was replaced daily for 7 days, when the cells were used for the experiments.

BMDMs were subjected to treatments with the following compounds: heme (25 μM; for 4 and 16 h), heme in combination with NAC (1 mM; LKT laboratories, Inc.) 1 h before heme treatment, with PPIX (25 μM, for 4 h; Sigma Aldrich), DFO (100 μM; Sigma Aldrich), allopurinol (1 mM; Sigma Aldrich), apocynin (100 μM; Sigma Aldrich), LPS (100 μg/mL, for 4 h; from L2880 E. coli, serotype 055:B5; Sigma Aldrich), or with polymyxin B sulfate salt (0.1 μg, 1 μg, and 10 μg/mL) (Sigma Aldrich).

**ROS production**

BMDMs were labeled with 2′,7′-dichlorodihydrofluorescein diacetate (2′,7′-DCFH-DA; Sigma Aldrich) at a concentration of 20 μM for 30 min at 37°C. The mean cellular fluorescence was observed in Leica fluorescence microscope (Leica DMI 6000B, Germany) and measured in fluorescence microplate reader (CLARIO star; BMG Labtech, Germany) at excitation of 488 ± 10 nm and emission of 520 ± 10 nm.

**Measurement of the intracellular iron content using total-reflection X-ray fluorescence spectrometry**

Intracellular iron content was measured using total-reflection X-ray fluorescence spectrometry (TXRF) (6). In brief, heme-treated and untreated BMDMs were rinsed with PBS and pelleted in precleaned reaction tubes. To avoid trace contamination, all materials were presoaked in 0.5% nitric acid (HNO₃) for 12 h, and before use, rinsed three times with ultrapure water (type I water, MilliQ Reference A; Merck Millipore, Germany). Cell pellets were digested in 1 mL precleaned concentrated HNO₃ (subboiled; DST-1000 Acid Purification System, Savillex) and briefly vortexed. Ten microliters of digested sample was pipetted on to a precleaned quartz glass carrier in duplicates and dried at 60°C. Each measurement was performed by a S2 Picofox benchtop TXRF with a Mo X-ray tube (high-efficiency module; Bruker Nano GmbH, Germany) and a live time of 500 s. A Bayesian deconvolution was applied to the spectra (optimized fit, max. stripping cycles: 100, step width: 1). As an internal standard, 10 μL of Gallium (Ga) solution in 2% HNO₃ was added to each sample (Gallium standard, 1:10 diluted; AAS Standard 1000 mg/L in 2% HNO₃, AVS Titrinorm, VWR Prolabo, Belgium). The iron content is measured relative to protein levels in the cells.

**Tissue heme and nonheme iron measurement and Perls’ staining**

Heme levels in the liver and the spleen were measured using the method described previously (46). In brief, tissues were homogenized in PBS and protein concentration was determined using BCA protein quantification kit from Pierce BCA660 Protein Assay Kit (Thermo Fisher Scientific; Rockford). In duplicates, 0.5 mL of 2 M oxalic acid (Sigma Aldrich) and 10 μg of protein were boiled at 95°C for 30 min. The nonboiling samples were used to assess the background fluorescence. All samples were brought to room temperature and centrifuged at 13,500 rpm for 5 min. Emission of fluorescence in samples was determined spectrophuorometrically (CLARIO star; BMG Labtech, Germany) at excitation/emission wave length at 405/662 nm. In parallel, a heme standard curve was run.

The nonheme iron content in the spleen was measured as reported previously (54). Iron deposition was revealed by Perls’ Prussian blue staining. Paraffin-embedded spleen tissue sections (of 4 μm) were mounted on frosted slides (VWR, Germany) and stained for iron in the presence or absence of 0.8% 3,3′-diaminobenzidine tetrahydrochloride hydrate (Sigma Aldrich) for 3–5 min.

**RNA isolation, reverse transcription, and real-time polymerase chain reaction**

Total RNA was isolated from the spleen or cells using Trizol reagent (Invitrogen) or RNeasy Midi kit (Qiagen, Hilden, Germany) according to the manufacturer’s instruction. RNA quality and quantity were controlled using the Nanodrop 2000 system (Thermo Scientific). RevertAid H Minus (M-MulV) reverse transcriptase (RT) (Fermentas), 5× RT reaction buffer (Fermentas), random primers (200 ng/μl; Invitrogen), and 10 mM dNTPs (Bioline, London, United Kingdom) were used to convert 1–2 μg of RNA to cDNA following the manufacturer’s instructions. Primers used in the study are listed in Supplementary Table S2.

Quantitative real-time polymerase chain reaction was carried out in 10 μL of reaction volume using SYBR Green I Dye (Invitrogen) on ABI ViiA-7 system (Applied Biosystems). The mRNA abundance of the gene of interest was calculated relative to the expression of the reference glyceraldehyde-3-phosphate dehydrogenase gene Gapdh using Δ∆CT method (35).

**Protein isolation and Western blot analysis**

Protein extracts were prepared as previously described (54). In brief, flash-frozen spleens or BMDMs were homogenized in RIPA lysis buffer (50 mM Tris-Cl pH 8.0/150 mM NaCl/1% nonidet P-40/0.5% deoxycholate/0.1% sodium dodecyl sulfate [SDS]) supplemented with the protease inhibitors [Complete Mini (25) ROC 11836153001; Roche Diagnostics, Mannheim, Germany] and phosphatase inhibitors (1 mM sodium orthovanadate (Na₃O₄Va)/25 mM sodium fluoride/1 mM phenylmethylsulfonylfluoride; Sigma Aldrich) for 30 min on ice. Cell debris was removed by centrifugation at 13,000 rpm for 15 min at 4°C and protein concentration was determined using the Pierce BCA660 Protein Assay Kit (Thermo Fisher Scientific; Rockford).

Equal amounts of protein extracts were diluted in 5× Laemmli buffer (0.34 Tris-HCl pH 6.8/0.7% SDS/0.6 M di-thiorethreitol/34% glycerol/bromphenol-blue) and subjected to a 10% SDS-polyacrylamide gel electrophoreses. After the transfer to nitrocellulose membranes (0.45 μm; BioRad), the membranes were blocked for 1 h in 5% milk powder (Sigma Aldrich) in TBST buffer (20 mM Tris-Cl pH 7.5/137.5 mM NaCl/0.1% Tween20 (Sigma Aldrich, Germany) and then blotted with antiferritoprotein (1:500; Alpha Diagnostics Ltd.), antitransferrin receptor 1 (1:500, Tfr1; Zymed laboratories), anti-cluster of differentiation 91 (CD91)/low-density lipoprotein-related protein 1 (1:10,000; Abcam), and antiferritin-H (1:1000 in 2% bovine serum albumin).
albumin; Cell Signaling Technology) following the manufacturer’s instructions. Membranes were washed and incubated with antirabbit horseshadish peroxidase-conjugated antibody (1:5000; Invitrogen). Reactions were carried out with Luminata Forte Western horseshadish peroxidase substrate kit (Millipore). As loading control, anti-β-actin (1:10,000; Sigma Aldrich) was used in Tris-buffered saline/Tween-20 for 1 h after which membranes were washed and further incubated with secondary antimouse polyclonal antibody (1:10,000; Invitrogen) for 1 h at room temperature. Membranes were washed before the addition of substrate and observed in chemiluminescence detector (BioRad).

The signals were quantified by scanning densitometry and computer-assisted image analysis.*

Statistical analyses

Data were analyzed using GraphPad Prism software and results are shown as mean ± standard error of mean. For the statistical analysis, a one- and two-way analysis of variance was applied, respectively, for the comparison of multiple groups. For pairwise comparisons, the Student’s t-test (two-tailed; unequal variance) was used. A probability value $p<0.05$ was deemed statistically significant.

Acknowledgments

We thank Professor E. Tolosano for the samples of sickle mice, Dr. B. Mayer for statistical analysis of the data, Professor J. Tuckermann and G. Caratti for the critical reading of the article, and the staff of the animal facility at the Ulm University. This work was supported by the German Research Foundation (DFG, VIU75/2-1, to M.V.S.) and by the Ulm University (to M.V.S.).

Authors’ Contributions

N.K.T. performed the experiments and analyzed the data; B.A., D.L., and S.V. assisted in experiments. F.V. analyzed sickle samples and discussed the data; K.W. and K.L. performed TXRF analysis and discussed the data; M.V.S. designed research, analyzed data, and wrote the article.

Author Disclosure Statement

No competing financial interests exist.

References

1. Altenhoffer S, Radermacher KA, Kleikers PW, Wingler K, and Schmidt HH. Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 23: 406–427, 2015.
2. Arruda MA, Barcellos-de Souza P, Sampaio AL, Rossi AG, Graca-Souza AV, and Barja-Fidalgo C. NADPH oxidase-derived ROS: key modulators of heme-induced mitochondrial stability in human neutrophils. Exp Cell Res 312: 3939–3948, 2006.
3. Bedard K and Krause KH. The NOX family of ROS-generating NADPH oxidas: physiology and pathophysiology. Physiol Rev 87: 245–313, 2007.
4. Belcher JD, Chen C, Nguyen J, Milbauer L, Abdulla F, Aleyash AI, Smith A, Nath KA, Hebbel RP, and Vercellotti GM. Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease. Blood 123: 377–390, 2014.
5. Belcher JD, Nath KA, and Vercellotti GM. Vasculotoxic and proinflammatory effects of plasma heme: cell signaling and cytoprotective responses. ISRN Oxidative Med 2013: pii: 831596, 2013.
6. Cerchiaio G, Manieri TM, and Bertuchi FR. Analytical methods for copper, zinc and iron quantification in mammalian cells. Metallomics 5: 1336–1345, 2013.
7. Chiabrando D, Vinchi F, Fiorito V, Mercurio S, and Tolosano E. Heme in pathophysiology: a matter of scavenging, metabolism and trafficking across cell membranes. Front Pharmacol 5: 61, 2014.
8. Chirico EN and Pialoux V. Role of oxidative stress in the pathogenesis of sickle cell disease. IUBMB Life 64: 72–80, 2012.
9. Chiu D and Lubin B. Oxidative hemoglobin denaturation and RBC destruction: the effect of heme on red cell membranes. Semin Hematol 26: 128–135, 1989.
10. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliafico E, Bosurgi L, Campanella A, Brunelli S, Manfredi AA, Apostoli P, Silvestri L, Camaschella C, and Rovere-Querini P. Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95: 1814–1822, 2010.
11. De Franceschi L, Daraio F, Filippini A, Carturan S, Mucitsch EM, Roetto A, and Camaschella C. Liver expression of hepcidin and other iron chaperones in two mouse models of beta-thalassemia. Haematologica 91: 1336–1342, 2006.
12. Delaby C, Pilar N, Goncalves AS, Beaumont C, and Canonne-Hergaux F. Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidin. Blood 106: 3979–3984, 2005.
13. Delaby C, Pilar N, Puy H, and Canonne-Hergaux F. Sequential regulation of ferroportin expression after erythropagocytosis in murine macrophages: early mRNA induction by haem, followed by iron-dependent protein expression. Biochem J 411: 123–131, 2008.
14. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, and Andrews NC. The iron exporter ferroportinSlc40a1 is essential for iron homeostasis. Cell Metab 1: 191–200, 2005.
15. Dutra FF, Alves LS, Rodrigues D, Fernandez PL, de Oliveira RB, Golenbock DT, Zamboni DS, and Bozza MT. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci U S A 111: E4110–E4118, 2014.
16. Dutra FF and Bozza MT. Heme on innate immunity and inflammation. Front Pharmacol 5: 115, 2014.
17. Ferring-Appel D, Hentze MW, and Galy B. Cell-autonomous and systemic context-dependent functions of iron regulatory protein 2 in mammalian iron metabolism. Blood 113: 679–687, 2009.
18. Figueiredo RT, Fernandez PL, Mourao-Sa DS, Porto BN, Dutra FF, Alves LS, Oliveira MF, Oliveira PL, Graca-Souza AV, and Bozza MT. Characterization of heme as activator of Toll-like receptor 4. J Biol Chem 282: 20221–20229, 2007.
19. Fortes GB, Alves LS, de Oliveira R, Dutra FF, Rodrigues D, Fernandez PL, Souto-Padron T, De Rosa MJ, Kellihier M, Golenbock D, Chan FK, and Bozza MT. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood 119: 2368–2375, 2012.

*(ImageJ; www://rsb.info.nih.gov/ij).*
20. Gaetano C, Massimo L, and Alberto M. Control of iron homeostasis as a key component of macrophage polarization. Haematologica 95: 1801–1803, 2010.

21. Ganz T. Heme oxygenase-1 as a regulator of second messenger gases. Annu Rev Pharmacol Toxicol 37: 517–554, 1997.

22. Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina P, Grady RW, and Rivella S. Ineffective erythropoiesis in beta-thalassemia is mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 109: 5027–5035, 2007.

23. Gatidis S, Foller M, and Lang F. Hemin-induced suicidal erythroyte death. Ann Hematol 88: 721–726, 2009.

24. Gozzelino R, Jeney V, and Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50: 323–354, 2010.

25. Hasan RN and Schaefer AI. Hemin upregulates Egf-1 expression in vascular smooth muscle cells via reactive oxygen species ERK-1/2-Erk-1 and NF-kappaB. Circ Res 102: 42–50, 2008.

26. Hebbel RP and Eaton JW. Pathobiology of heme interaction with the erythrocyte membrane. Semin Hematol 26: 136–149, 1989.

27. Hvidberg V, Maniecki MB, Jacobsen C, Hojrup P, Moller HI, and Moestrup SK. Identification of the receptor scavenging hemopexin-heme complexes. Blood 106: 2572–2579, 2005.

28. Jeney V, Balla J, Yachie A, Varga Z, Vercellotti GM, Eaton JW, and Balla G. Pro-oxidant and cytotoxic effects of circulating heme. Blood 100: 879–887, 2002.

29. Kaul DK, Liu XD, Choong S, Belcher JD, Vercellotti GM, and Hebbel RP. Anti-inflammatory therapy ameliorates heme-induced endothelial toxicity in mouse models. Circulation 117: 1690–1700, 2008.

30. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, and Ganz T. Identification of erythroferrone as an erythroid differentiation factor and an endogenous negative regulator of hepcidin expression. Am J Physiol Heart Circ Physiol 287: H293–H301, 2004.

31. Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, and Ganz T. Identification of erythroferrone as an erythroid differentiation factor and an endogenous negative regulator of hepcidin expression. Am J Physiol Heart Circ Physiol 287: H293–H301, 2004.

32a. Kumar Tangudu N and Vujic Spasic M. Heme activates macrophage hepcidin expression via toll like receptor 4 and extracellular signal-regulated kinases signaling pathway. Clin Pharmacol Biopharm 6: 1, 2017.

33. Larsen R, Gozzelino R, Jeney V, Tokaji L, Bozza FA, Japiassu AM, Bonaparte D, Cavalcante MM, Chora A, Ferreira A, Marguti I, Cardoso S, Sepulveda N, Smith A, and Soares MP. A central role for free heme in the pathogenesis of severe sepsis. Sci Transl Med 2: 51ra71, 2010.

34. Latunde-Dada GO, Vulpe CD, Anderson GJ, Simpson RJ, and McKie AT. Tissue-specific changes in iron metabolism genes in mice following phenylhydrazine-induced haemolysis. Biochim Biophys Acta 1690: 169–176, 2004.

35. Livak KJ and Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402–408, 2001.
gestion in a mouse model of heme overload. *Am J Pathol* 173: 289–299, 2008.

54. Vujić Spasić M, Sparla R, Mleczko-Sanecka K, Migas MC, Breitkopf-Heinlein K, Dooley S, Vaulont S, Fleming RE, and Muckenthaler MU. Smad6 and Smad7 are co-regulated with hepcidin in mouse models of iron overload. *Biochim Biophys Acta* 1832: 76–84, 2013.

55. Wagener FA, Eggert A, Boerman OC, Oyen WJ, Verhofstad A, Abraham NG, Adema G, van Kooyk Y, de Witte T, and Figdor CG. Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. *Blood* 98: 1802–1811, 2001.

56. Wagener FA, Feldman E, de Witte T, and Abraham NG. Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. *Proc Soc Exp Biol Med* 216: 456–463, 1997.

57. Zhang Z, Zhang F, An P, Guo X, Shen Y, Tao Y, Wu Q, Zhang Y, Yu Y, Ning B, Nie G, Knutson MD, Anderson GJ, and Wang F. Ferroportin1 deficiency in mouse macrophages impairs iron homeostasis and inflammatory responses. *Blood* 118: 1912–1922, 2011.

58. Zhang Z, Zhang F, Guo X, An P, Tao Y, and Wang F. Ferroportin1 in hepatocytes and macrophages is required for the efficient mobilization of body iron stores in mice. *Hepatology* 56: 961–971, 2012.

Address correspondence to:
Prof. Dr. Maja Vujić Spasić
Institute of Comparative Molecular Endocrinology
University of Ulm
Ulm 89081
Germany

E-mail: maja.vujic@uni-ulm.de

Date of first submission to ARS Central, April 5, 2017; date of final revised submission, November 29, 2017; date of acceptance, November 30, 2017.

### Abbreviations Used

- **BMDMs** = bone marrow-derived macrophages
- **CD91** = cluster of differentiation 91
- **DFO** = desferoxamine
- **Fpn1** = ferroportin1
- **Gapdh** = glyceraldehyde-3-phosphate dehydrogenase
- **HbS mice** = sickle cell disease mouse model
- **HCl** = hydrochloric acid
- **Hmox1** = heme oxygenase 1
- **i.p.** = intraperitoneal
- **i.v.** = intravenous
- **LPS** = lipopolysaccharide
- **LRP1** = low-density lipoprotein-related protein 1
- **NAC** = N-acetyl-L-cysteine
- **NADPH** = nicotinamide adenine dinucleotide phosphate
- **PBS** = phosphate-buffered saline
- **PPIX** = protoporphyrin IX
- **ROS** = reactive oxygen species
- **SDS** = sodium dodecyl sulfate
- **SEM** = standard error of mean
- **TfR1** = transferrin receptor 1
- **Tlr4** = toll-like receptor-4
- **TXRF** = total-reflection X-ray fluorescence spectrometry